



UNIVERSITÀ
degli STUDI
di CATANIA

MASTER IN DRUG
REGULATORY AFFAIRS

CERD

CENTRO PER LA RICERCA
E LA CONSULTAZIONE
IN DISCIPLINE REGOLATORIE
DEL FARMACO

CENTRE FOR RESEARCH IN
REGULATORY AFFAIRS AND HTA

Coordinator: Filippo Drago

EUROPEAN REGULATORY CONFERENCE

Forum of European Regulatory Experts
for the minimization of interstate discrepancies

Towards a European Pharmaceutical Harmonization: Clinical evidence versus clinical benefit

“Adaptation processes in the regulatory world are too long: we cannot wait that a change is made through an adaptation process, we have to anticipate the adaptation”.
(Francis Megerlin)

Catania, February 21st, 2020

**Biological Tower, Via S. Sofia, 97
Aula Magna “Umberto Scapagnini”**

SCIENTIFIC PROGRAM

- 09:30-10:30** Registration
- 10:30-10:45** Welcome address
Filippo Drago - Coordinator Master in Drug Regulatory Affairs, Catania
Francesco Priolo - University Rector
Alessandro Mugelli - Past-President SIF
- Chairman **Francis Megerlin** - EUCOR, University of Strasbourg (France)
- 10:45-11:30** Introductory lecture
Facing old and new difficulties towards a European Pharmaceutical Union
Guido Rasi - Executive Director, European Medicines Agency, Amsterdam (The Netherlands)
- 11:30-12:00** Value-based pricing of drugs in the UK
Kenneth Paterson - Professor emeritus, University of Glasgow (UK)
- 12:00-12:30** How clinical effectiveness is used in France to triage innovative drugs?
Olivier Wong - Chief Medical Officer, Medi Qualité Omega (France)
- 12:30-13:00** The comparator in clinical trials: the German model
Jan Geldmacher - AKDAE, Berlin (Germany)
- 13:00-13:30** Early access procedures: is it always an advantage? Do we need a harmonization?
Patrizia Popoli - President, Scientific Committee, Italian Agency for Medicines (Italy)
- 13:30-14:30** Lunch break
- Chairman **Olivier Wong** - Chief Medical Officer, Medi Qualité Omega (France)
- 14:30-15:00** Early access programs in Italy: pros and cons
Claudio Jommi - SDA Bocconi School of Management, Milan (Italy)
- 15:00-15:30** Innovation in drug development: do we need a common parameter?
Francis Megerlin - EUCOR, University of Strasbourg (France)
- 15:30-16:00** The issues around a harmonized HTA approach in Europe from a German system's perspective
Frank-Ulrich Fricke - University of Nurnberg (Germany)
- 16:00-16:30** Funding orphan medicinal products beyond price
Oriol Morales Solá - Chief Executive Officer, Health Innovation Technology Transfer (Spain)
- 16:30-17:00** Influence of Europe-Japan interactions on the European drugs regulatory and reimbursement systems
Isao Kamae - University of Tokyo (Japan)
- 17:00-17:30** Concluding remarks
Filippo Drago

With the unconditional support of



Registration
<https://form.jotform.com/200072669014347>

Organizing Secretariat

Comitato Promotore di iniziativa atte a favorire la formazione e l'aggiornamento continuo in ambito medico-scientifico
e-mail: congressi@coprom.it

Under the patronage of



SOCIETÀ ITALIANA DI FARMACOLOGIA